Clinical Trials Logo

Clinical Trial Summary

This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=452) that did not respond or tolerate first-line fluoxetine therapy will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or GLAD-PC guided prescribing (control intervention).


Clinical Trial Description

Goal: To test the efficacy of pharmacogenetic-guided antidepressant prescribing for adolescents with depression. Background: For an adolescent with moderate to severe depression, antidepressant medication is prescribed, often in combination with psychotherapy. The class of antidepressants recommended for use is selective serotonin reuptake inhibitors (SSRIs) with fluoxetine recommended as the first-line medication, and four other SSRIs recommended for consideration (sertraline, citalopram, escitalopram, fluvoxamine) if the adolescent does not respond or tolerate fluoxetine. For most adolescents, medication prescribing, and monitoring will be managed by a primary care physician or community pediatrician rather than by a mental health care provider, and guidelines exist to support this management (Guidelines for Adolescent Depression in Primary Care, GLAD-PC). However, GLAD-PC does not account for SSRI metabolism phenotypes that could change whether the SSRI selected is efficacious or tolerated. Our team of researchers, clinician scientists, patient partners, and primary care providers has designed a trial to test the impact of accounting for metabolism phenotypes, through pharmacogenetic-guided antidepressant prescribing, on adolescent outcomes, experiences, and health care utilization. Principal Question: Compared to GLAD-PC informed prescribing, does pharmacogenetic-guided prescribing for depressed adolescents who have not responded or tolerated first-line fluoxetine therapy, have superior efficacy following 12-weeks of therapy with an alternative SSRI? The Trial: This is a parallel arm randomized controlled trial. Adolescents aged 12-17 years (n=452) that did not respond or tolerate first-line fluoxetine therapy will be randomly allocated to receive pharmacogenetic-guided antidepressant therapy (experimental intervention) or GLAD-PC guided prescribing (control intervention). Participants and prescribing physicians will be blinded to which intervention was received. The primary outcome is depressive symptom remission at 12 weeks measured using the Quick Inventory of Depressive Symptomatology - Adolescent (17-item) (QIDS-A17). Secondary outcomes include side effects, role functioning, medication adherence, and health-related quality of life measured 4-, 8-, and 12-weeks after intervention initiation as well as cost-effectiveness. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05965401
Study type Interventional
Source University of Calgary
Contact Laina McAusland, MSc
Phone 403-210-6353
Email gap@ucalgary.ca
Status Recruiting
Phase N/A
Start date October 25, 2023
Completion date December 2027

See also
  Status Clinical Trial Phase
Recruiting NCT05437588 - Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents N/A
Recruiting NCT04719897 - Life Experiences in Adolescents and the Development of Skills N/A
Active, not recruiting NCT05376358 - Evaluation of MoodRing on Improving the Quality of Depression Management in Adolescents N/A
Recruiting NCT05691439 - Mechanisms of Depression and Anhedonia in Adolescents: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Recruiting NCT06139861 - Better Sleep Study N/A
Recruiting NCT04747340 - Clinical Effectiveness of TARA Compared to Standard Treatment for Adolescents and Young Adults With Depression N/A
Recruiting NCT06273995 - Telehealth Behavioral Activation for Teens N/A
Recruiting NCT05712772 - Neuro-affective Response to Light in Depressed Adolescents and Young Adults N/A
Completed NCT06213142 - Developing the Unified Protocol-Single Session Experience Platform for Adolescent Mental Health N/A
Recruiting NCT05329441 - Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression
Completed NCT05300204 - Evaluation of a Website to Improve Depression Literacy in Adolescents With Depression N/A
Completed NCT05300217 - Evaluation of a Website to Improve Depression Literacy in Adoldescents N/A
Recruiting NCT06193772 - Increasing Treatment Response Rates in Depressed Adolescents Via Feedback-Informed IPDT N/A
Completed NCT05335564 - Evaluation of a Website to Improve Depression Literacy in Parents of Adolescents With Depression N/A
Completed NCT05326178 - Evaluation of a Website to Improve Depression Literacy in Parents of Healthy Adolescents N/A
Completed NCT04719949 - Shaping Actions and Responses to Emotions N/A
Not yet recruiting NCT05865834 - Improvement of Mental Health in Adolescents Using E-health Interventions N/A
Recruiting NCT06387108 - Evaluation of a Training Course for Educational Professionals N/A
Not yet recruiting NCT05804877 - Online MBCT Program for University Students N/A
Recruiting NCT05617495 - Mindfulness-Based fMRI Neurofeedback for Depression N/A